Dhiren Kumar, MD
Nephrology · Richmond, VANPI 1629162938
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,125 of the $8,404 with a category attached, or 61.0%. Organox Ltd accounts for 72.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $8,041, more than ten times the $97 reported in 2019.
Across 22 payments — averaging $381.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organox Ltd$6K
- One Lambda, Inc.$1K
- Apellis Pharmaceuticals, Inc.$445
- Sanofi-aventis U.S. LLC$136
- Pacira Pharmaceuticals Incorporated$97
- Sanofi$91
- plus $203 from 4 others
Across 148 payments — averaging $1362.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$202K
What the payments were for
- Consulting fees$1,35016%
- Speaking & faculty fees$5,12561%
- Travel & lodging$6678%
- Food & beverage$1,26115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organox Ltd | 6 | $6,082 |
| One Lambda, Inc. | 1 | $1,350 |
| Apellis Pharmaceuticals, Inc. | 5 | $445 |
| Sanofi-aventis U.S. LLC | 1 | $136 |
| Pacira Pharmaceuticals Incorporated | 1 | $97 |
| Sanofi | 1 | $91 |
| Veloxis Pharmaceuticals, Inc. | 3 | $61 |
| Novartis | 1 | $58 |
| AstraZeneca | 2 | $44 |
| Kerecis Limited | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- METRA$5,945
- THYMOGLOBULIN$136
- Empaveli$106
How this compares
$8,404 in reported general payments places this provider in the 85th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $47,926 |
| OzempicSemaglutide | 49 | $46,478 |
| EliquisApixaban | 56 | $42,922 |
| Envarsus XrTacrolimus | 20 | $33,327 |
| JanuviaSitagliptin Phosphate | 14 | $11,958 |
| Atovaquone | 20 | $11,403 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $7,790 |
| TradjentaLinagliptin | 12 | $6,319 |
| Valganciclovir Hcl | 43 | $6,094 |
| Cinacalcet Hcl | 72 | $5,282 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $4,725 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $4,295 |
| Nifedipine ErNifedipine | 82 | $1,886 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 28 | $1,541 |
| Methenamine Hippurate | 39 | $1,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $44 | $7,79013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 298 nephrology providers in Virginia.
Other nephrology in Richmond
- Gaurav GuptaRichmond$168K
- Todd GehrRichmond$17K
- Nilang PatelRichmond$13K
- Jason KiddRichmond$13K
- Domenic SicaRichmond$10K
- Lozina DanevaRichmond$7K
- Ari HirschRichmond$6K
- Shreyank TripathiRichmond$5K
- Sandy GibsonRichmond$5K
- Richard GayleRichmond$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.